The Australian Immunisation Handbook 10th Edition 2013

Germany indicates that no case of vaccine-induced congenital rubella syndrome
occurred among more than 500 women inadvertently vaccinated with rubella
vaccine during pregnancy, whose pregnancies continued. 53 In an Iranian study
performed after mass vaccination with a measles–rubella vaccine, 117 susceptible
women were inadvertently vaccinated while pregnant or became pregnant
within 3 months after vaccination. There were no CRS-related abnormalities
among the infants born to these women. 54 Based on this evidence, the vaccine
cannot be considered to be teratogenic, and termination of pregnancy following
inadvertent vaccination is not indicated. 1,8 (See also 3.3.2 Vaccination of women who
are planning pregnancy, pregnant or breastfeeding, and preterm infants.)
4.18.10 Precautions
For additional precautions related to MMR and MMRV vaccines, see 4.9 Measles
and 4.22 Varicella.
Vaccination with other live attenuated parenteral vaccines
If MMR or MMRV vaccine is not given simultaneously with other live attenuated
parenteral vaccines (e.g. varicella, BCG, yellow fever), the vaccines should be
given at least 4 weeks apart.
Vaccination after immunoglobulin or blood product administration
Administration of a MMR or MMRV vaccine should be delayed after
administration of immunoglobulin-containing products. After receipt of
immunoglobulin-containing blood products, the expected immune response
to measles, mumps, rubella and varicella vaccination may be impaired. 7,55,56
MMR-containing vaccines should not be given for between 3 and 11 months
following the administration of immunoglobulin-containing blood products.
The interval between receipt of the blood product and vaccination depends on
the amount of immunoglobulin in each product, and is indicated in 3.3 Groups
with special vaccination requirements, Table 3.3.6 Recommended intervals between
either immunoglobulins or blood products and MMR, MMRV or varicella vaccination. 55
For further information, see 3.3.4 Vaccination of recent recipients of normal human
immunoglobulin and other blood products.
Recent blood transfusion with washed red blood cells is not a contraindication to
MMR or MMRV vaccines.
MMR vaccine may be administered concomitantly with, or at any time in
relation to, anti-D immunoglobulin, but at a separate injection site. Anti-D
immunoglobulin does not interfere with the antibody response to vaccine. 1,3,8
Immunoglobulin or blood product administration after vaccination
Immunoglobulin-containing products should not be administered for 3 weeks
following vaccination with rubella-containing vaccines, unless the benefits
exceed those of vaccination. If immunoglobulin-containing products are
administered within this interval, the vaccinated person should either be
PART 4 VACCINE-PREVENTABLE DISEASES 393
4.18 RUBELLA